Quidelortho (QDEL) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Quidelortho Corp  (NASDAQ: QDEL)


Quidelortho's Gross Profit Margin by quarter

Trends, Rankings, Statistics



QDEL Gross Profit Margin (Jun 28 2026)
Q2
(Mar 29 2026)
Q1
(Dec 28 2025)
Q4
(Sep 28 2025)
Q3
(Jun 29 2025)
Q2
Y / Y Revenue Change 2.77 %
Seq. Revenue Change 1.79 %
Revenue In Millions $630.90
Gross Profit Margin 43.26 %
Gross Profit Margin Total Ranking # 1989
Gross Profit In Millions $272.90
Y / Y Gross Profit Change -0.73 %
Seq. Gross Profit Change 3.45 %


Commenting Second Quarter 2026 Gross Profit Margin
Quidelortho Corp Gross Profit grew by 3.45 % in Q2 sequentially to 273 millions, while Revenue increased by 1.79 %, this led to improvement in the company's Gross Profit Margin to 43.26 %, Gross Profit Margin remained below Quidelortho Corp average.


Observing second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 6 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1989, from total ranking in the previous quarter at 2082.
Learn about Gross Margin
QDEL's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 7
Healthcare Sector # 344
Overall # 1972

Gross Profit Margin Statistics
High Average Low
86.69 % 58.55 % 42.56 %
(Dec 31 2020)   (Mar 29 2026)




Other Gross Profit Margin Profitability Ratios
QDEL's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
QDEL's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for QDEL's Competitors
Gross Profit Margin Profit Margin for Quidelortho's Suppliers
Gross Profit Margin Profit Margin for QDEL's Customers

You may also want to know
QDEL's Annual Growth Rates QDEL's Profitability Ratios QDEL's Asset Turnover Ratio QDEL's Dividend Growth
QDEL's Roe QDEL's Valuation Ratios QDEL's Financial Strength Ratios QDEL's Gross Profit Growth
QDEL's Roa QDEL's Inventory Turnover Ratio QDEL's Growth Rates QDEL's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 28 2026, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginJun 28 2026 MRQ Gross ProfitJun 28 2026 MRQ Revenue
Myriad Genetics Inc   66.60 %$ 127.000  Millions$ 190.700  Millions
Insight Molecular Diagnostics Inc   65.69 %$ 0.157  Millions$ 0.239  Millions
Idexx Laboratories Inc  64.04 %$ 779.087  Millions$ 1,216.585  Millions
Lantheus Holdings Inc   62.30 %$ 241.855  Millions$ 388.180  Millions
Neogen Corporation  47.80 %$ 107.800  Millions$ 225.536  Millions
Quidelortho Corp  43.26 %$ 272.900  Millions$ 630.900  Millions
Alpha Teknova Inc   40.09 %$ 4.885  Millions$ 12.185  Millions
Immucell Corporation  33.92 %$ 2.437  Millions$ 7.186  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.